Additionally, it proposes the necessity of therapies that amplify the reduced systemic T cells and induce a tumor-reactive composition of CD8 T cells within the tumor, ensuring an adequate stem-like subset highly responsive to anti-PD-1. This evidence concerns the gene CD8A and neoplasm.